One required a physical, and she found out she had lung cancer. It also sets up a duel between Loxo and another biotechnology firm, Blueprint Medicines, which showed off data from another RET drug in April. Tumors shrank in 45% of 22 patients with medullary thyroid cancer who had mutations in the RET gene. He said it's too soon to compare the Blueprint and Loxo data sets. But thyroid cancer could be more complicated, he says, because there are already approved drugs.

Source: Forbes June 02, 2018 14:15 UTC